Abstract:Objective:To compare the clinical efficacy of allogeneic peripheral blood stem cell transplantation(Allo-PBSCT),allogeneic bone marrow transplantation(Allo-BMT) and Allo-PBSCT plus Allo-BMT for the treatment of severe aplastic anemia(SAA).Methods:Thirty-seven patients with SAA received HLA-matched sibling donor stem cell transplantation(n=11,Allo-PBSCT group.n=14,Allo-BMT group.n=12,Allo-PBSCT plus BMT group).The mean time of reconsitution of neutrophils(Neu) and platelets(Plt),short tandem repeats(STR)in detecting the engratment,the incidence of infection with agranulocytosis,and graft versus host diseases(GvHD) were observed.The three-year incidence of graft failure(GF),mortality and disease-free survival(DFS) after transplantation were also investigated.Results:The mean time of reconsitution of Neu was(13.5±2.3) days、(21.2±3.5) days and(14.7±2.4) days in Allo-PBSCT group,Allo-PBSCT plus BMT group and Allo-BMT group respectively.Significant differences were observed between the front two groups and the latter group(P<0.05).The mean time of reconsitution of Plt was(24±4) days、(22±5) days and(23±5)days respectively in Allo-PBSCT group,Allo-PBSCT plus BMT group and Allo-BMT group respectively No statistical difference among the three groups.Full donor chimerism was confirmed in all 37 patients at post-tranplant day28.The incidence of infection with agranulocytosis of Allo-PBSCT group and Allo-PBSCT plus BMT group was 9% and 17% respectively and were lower obviously than that in Allo-BMT group which was 57% and there were statistical differences between the front two groups and the latter group(P<0.05).The incidence of GvHD of Allo-PBSCT group was 36% and no GvHD happened in Allo-BMT group and Allo-PBSCT plus BMT group and the statistical differences between the front group and the latter groups was positive respectively(P<0.05).The three-year incidence of GF,mortality and DFS in PBSCT group was 36.3%,9.0% and 63.6% respectively.All patients in Allo-PBSCT plus BMT group and Allo-BMT group survived with disease-free and the all STRs showed stable.The incidence of GF in Allo-PBSCT group was higher(P<0.05) and the probability of DFS was lower than that in Allo-PBSCT plus BMT group and Allo-BMT group(P<0.05).Conclusions:Allo-PBSCT plus BMT can be chosen preferentially because of its quicker reconsitution of Neu,lower incidence of infection with agranulocytosis,lower incidence of GF and higher probability of DFS.

Pharmaceutical Care for 2 Cases of allo-PBSCT by Clinical Pharmacist

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Impact of a Clinical Pharmacist-Led Guidance Team on Cancer Pain Therapy in China: a Prospective Multicenter Cohort Study.

Pharmaceutical Care for a Patient with SCLC Postchemotherapy

Practice of Pharmaceutical Care in Chemotherapy for One Patient with Advanced Breast Cancer by Clini-cal Pharmacists

Pharmaceutical care performed by clinical pharmacists for one case of acute lymphocytic leukemia patient with infections

Allogenetic peripheral blood stem cell transplantation for patients with acute/chronic leukemia:clinical observation in 52 cases

[Allogeneic Peripheral Blood Stem Cell Transplantation in the Treatment of Hematologic Malignancies].

Pharmaceutical Care of One Case with Pulmonary Infection and Impaired Immune Function

Pharmaceutical Care of Chemotherapy for Patients with Double Primary Gastrointestinal Tumors Complicated with Heart Diseases by Clinical Pharmacists

Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation for Patients with Hematologic Malignancies.

A study of pharmacists-joint total parenteral nutrition in haematopoietic cell transplantation in accord with diagnosis related groups: A retrospective clinical research

Pharmaceutical care of clinical pharmacist on patients with Pneumocystis carinii pneumonia after renal transplantation

Clinical analysis of allogeneic peripheral blood stem cell transplantation on treating myelodysplastic syndrome in 8 cases

Allogeneic peripheral blood stem cell transplantation for 75 cases of hematologic malignancies]

Clinical Analysis on Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in 283 Cases

Clinical Analysis on Autologous Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in 206 Cases

Clinical Analysis of Autologous Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in 231 Cases

Study on preventing and treating graft-versus-host disease in 21 cases with allogeneic peripheral blood stem cell transplantation for the treatment of leukemia

Pharmaceutical Practice of Clinical Pharmacist Participating in the Treatment of 2 Cases of Repeated Use of L-asparaginase Induced Pediatric Asthma

Effect of different methods of haematopoietic stem cell transplantation for the treatment of severe aplastic anemia